Related Experiment Video
Updated: Jun 27, 2026
Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
Published on: March 25, 2016
Diagnosis and therapy of neutropenia in large granular lymphocyte leukemia
Sanjay R Mohan1, Jaroslaw P Maciejewski
1Experimental Hematology and Hematopoiesis Section, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Insights
T-cell large granular lymphocyte leukemia (T-LGLL) is a chronic T-cell disorder often causing low blood counts. Immunosuppressive therapies can manage symptoms, but long-term treatment is frequently required.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- T-cell large granular lymphocyte leukemia (T-LGLL) is a chronic clonal lymphoproliferation of cytotoxic T cells.
- It is frequently associated with immune-mediated cytopenias, including neutropenia and anemia.
- Pathophysiology involves cytokine effects and direct cytotoxicity to hematopoietic precursors.
Purpose of the Study:
- To review the diagnostic challenges of T-cell large granular lymphocyte leukemia.
- To discuss the therapeutic options for T-cell large granular lymphocyte leukemia.
Main Methods:
- Review of existing literature on T-LGLL diagnosis and treatment.
- Analysis of current therapeutic strategies, including immunosuppressive agents and alternative regimens.
Main Results:
- Immunosuppressive therapies like cyclosporine, methotrexate, and cyclophosphamide are commonly used, though formal trial data and response rates are limited.
- Alternative regimens, including antithymocyte globulin and monoclonal antibodies, have shown efficacy in refractory cases.
- A majority of patients eventually require immunosuppressive therapy for symptomatic cytopenias.
Conclusions:
- T-LGLL can present indolently or with significant cytopenias.
- While chronic immunosuppressive therapy is often necessary, various agents can be used successfully.
- Further formal trials are needed to establish definitive response rates for T-LGLL treatments.
Purpose Of Review:
T-cell large granular lymphocyte leukemia is a chronic clonal lymphoproliferation of cytotoxic T cells often associated with immune-mediated cytopenias. The pathophysiology of cytopenias includes cytokine effects and direct antigen-specific cytotoxicity to hematopoietic precursors. This review will address the diagnostic challenges of and therapeutic options for T-cell large granular lymphocyte leukemia.
Recent Findings:
Immunosuppressive therapy, with cyclosporine, methotrexate, and oral cyclophosphamide, is often used, but formal trials have not been performed and response rates are poorly established. In refractory cases, alternative regimens such as antithymocyte globulin or monoclonal antibody therapy have exhibited hematologic response.
Summary:
T-cell large granular lymphocyte leukemia may assume an indolent course but sometimes manifests with significant cytopenias. A majority of patients will ultimately require immunosuppressive therapy due to symptomatic neutropenia or anemia. In these cases, a variety of agents maybe used successfully though chronic therapy is often necessary.
